Swedish MedTech startup MedVasc raises €917k to improve anaesthetic procedure when treating varicose veins

Lund-based MedVasc AB, a Swedish MedTech company, announced today the successful closing of a €917k financing round to support the final product development phase for their catheter device and preparation for FDA regulatory approval in the United States.

The financing round attracted both existing owners and new investors.

“We are very pleased with the continued confidence from our investors,” says Cathrin Johansson, CEO of MedVasc AB. “This investment gives us the opportunity to take decisive steps towards reaching the US market, which is an important milestone in our growth journey.”

MedVasc AB was founded in 2013 by Michael Åkesson and has during the last years, developed a final prototype, been granted patents and trademarks in all prioritised markets, and performed a first-in-man clinical study.

Åkesson is a senior consultant of interventional radiology and has an experience of over twenty years with catheter based treatments and diagnosis. Previously he was the Head of the Division of Endovascular Surgery at the Vascular Department, University Hospital SUS Malmö. He now works as a senior consultant at the Scandinavian Venous Centre, Malmö.

He is the main owner of MedVASC AB and the inventor behind Solutio.

MedVasc has developed and patented the medical device Solutio, designed to improve the anaesthetic procedure when treating varicose veins. For investigational use only. The Solutio catheter has not been evaluated by the FDA and is not yet available for sale in the USA.

Solutio is designed to enable safe and precise local anesthesia during minimally invasive vascular procedures, e.g. varicose veins, (compatible with thermal ablation treatment fibers), offering a new level of control and patient comfort for clinicians treating chronic venous disorders.

The primary focus of the investment will be to fund the production and testing of the final design of Solutio, required for FDA clearance. Regulatory submission is planned for the first half of 2026.

In addition, MedVasc will raise an additional round during 2025 for investments in clinical and preclinical activities required for FDA clearance.

MedVasc is also participating in SmiLe’s incubator programme – also based in Lund. SmiLe is a leading venture hub that specialises in advancing life science and FoodTech startups from concept to commercialisation. To date, their flagship incubator programme has supported over 110 startups, facilitating their collective acquisition of more than €1.05 billion in venture capital and contributing to 21 successful IPOs.

The post Swedish MedTech startup MedVasc raises €917k to improve anaesthetic procedure when treating varicose veins appeared first on EU-Startups.